Advertisement
News
Advertisement

Resolvyx, Celtic Pharma form deal around dry eye therapy

Tue, 10/26/2010 - 10:33am
Mass High Tech: The Journal of New England Technology

Resolvyx Pharmaceuticals Inc., a Bedford-based developer of anti-inflammatory drugs, and Celtic Pharma, based in the U.S. Virgin Islands, have entered into a deal relating to Resolvyx’s dry-eye syndrome treatment.

The agreement gives Celtic Pharma an exclusive option to acquire and license rights to RX-10045, the late-stage treatment for dry eye syndrome developed by Resolvyx. Celtic Pharma also has the option to license rights to another eye treatment.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading